Skip to search formSkip to main contentSkip to account menu

ODM-201

Known as: AR Antagonist ODM-201, Antiandrogen ODM-201, ODM 201 
A formulation containing an androgen receptor (AR) antagonist with potential antineoplastic activity. AR antagonist ODM-201 binds to ARs in target… 
National Institutes of Health

Related topics

Related topics

6 relations
AR protein, humanInhibition of Cell ProliferationNCIt Antineoplastic Agent TerminologyNegative Regulation of Receptor Activation

Broader (1)

ORM-16497

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2016
2016
The Ongoing Challenges of Targeting the Androgen Receptor.
2016
2016
ARAMIS trial: Efficacy and safety of ODM-201 in men with high-risk nonmetastatic castration-resistant prostate cancer.
TPS5094Background: Treatment for nonmetastatic castration-resistant prostate cancer (nmCRPC) other than continuing androgen… 
2015
2015
ARAMIS trial: Efficacy and safety phase 3 trial of ODM-201 in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).
TPS5080 Background: There is no standard treatment for nmCRPC besides continuing androgen deprivation therapy (ADT). Preventing… 
Review
2015
Review
2015
[New therapies in metastatic castration resistant prostate cancer].
2015
2015
Pharmacokinetics, activity, and safety of ODM-201 in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer: An open-label phase I trial with long-term extension.
230 Background: The open phase I trial, ARAFOR, with long-term extension evaluated pharmacokinetics (PK), antitumor activity and… 
2014
2014
Bone and soft tissue response from a phase I/II study with ODM-201 in metastatic castration-resistant prostate cancer (mCRPC).
102^ Background: ODM-201 is a novel potent full androgen receptor (AR) inhibitor for CRPC. ODM-201 has excellent nonclinical… 
Review
2014
Review
2014
ODM-201 and the CNS: A clinical perspective.
275^ Background: ODM-201 is a potent, new generation androgen receptor inhibitor with activity in preclinical in vivo and in… 
2013
2013
ODM-201, a new generation androgen receptor inhibitor for castration-resistant prostate cancer: Preclinical and phase I data.
65^ Background: Castration resistant prostate cancer (CRPC) is characterized by persistent, high level androgen receptor (AR… 
Review
2012
Review
2012
Putting the brakes on continued androgen receptor signaling in castration-resistant prostate cancer
Review
2004
Review
2004
Metamodels for RDF Schema and OWL
This paper presents the working draft MOFTM (Meta-Object Facility) metamodels for the Resource Description Framework (RDF Schema… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)